PMID- 38157036
OWN - NLM
STAT- MEDLINE
DCOM- 20240418
LR  - 20240418
IS  - 1434-4726 (Electronic)
IS  - 0937-4477 (Linking)
VI  - 281
IP  - 5
DP  - 2024 May
TI  - Temporal trends of blood eosinophilia in severe uncontrolled CRSwNP treated with 
      dupilumab: a real-life study.
PG  - 2429-2440
LID - 10.1007/s00405-023-08417-8 [doi]
AB  - PURPOSE: Induced eosinophilia is commonly related to dupilumab treatment. We 
      analysed the temporal trends of blood eosinophilia in patients with severe 
      uncontrolled CRSwNP during the first year of treatment with dupilumab in 
      real-life setting to evaluate its correlation with outcomes of response and 
      adverse events (AEs). METHODS: Seventy-four patients with severe uncontrolled 
      CRSwNP treated with dupilumab at our institution were enrolled. At each visit, we 
      evaluated AEC, outcomes of response to treatment and AEs. RESULTS: A significant 
      increase in AEC was observed since the first month with a peak at 3 months; at 12 
      months, the values returned comparable to those at baseline. A >/= 50% increase of 
      the baseline AEC with a value greater than 500 cells/mm(3) was documented in 
      38/74 patients (Group A) regardless of the time of observation, whereas in 36/74 
      patients (Group B), no changes were observed. Analysing the blood eosinophilia 
      trend over time in group A, we observed a temporary eosinophilia with early onset 
      (within 6 months), persistent eosinophilia with early onset, and eosinophilia 
      with late onset. No differences in terms of outcomes of response to treatment or 
      AEs were found between Group A and Group B, or between patients who developed an 
      AEC >/= 1500 cells/mm(3) or not. CONCLUSION: In our series, we observed that an 
      increase in AEC with different temporal trends may be observed in CRSwNP patients 
      during the first year of treatment with dupilumab. In our series, eosinophilia is 
      not correlated with a negative outcome of response to treatment or a risk of AEs.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - De Corso, Eugenio
AU  - De Corso E
AUID- ORCID: 0000-0001-5761-7018
AD  - Unit of Otorhinolaryngology and Head-Neck Surgery, "A. Gemelli" Hospital 
      Foundation IRCCS, 00168, Rome, Italy.
FAU - Montuori, Claudio
AU  - Montuori C
AUID- ORCID: 0000-0003-2070-0314
AD  - Department of Head-Neck and Sensory Organs, Catholic University of Sacred Heart, 
      00168, Rome, Italy. claudio_montuori@libero.it.
FAU - Baroni, Silvia
AU  - Baroni S
AD  - Unit of Chemistry, Biochemistry and Molecular Biology, "A. Gemelli" Hospital 
      Foundation IRCCS, 00168, Rome, Italy.
AD  - Department of Basic Biotechnological Sciences, Intensive Care and Perioperative 
      Clinics, Catholic University of Sacred Heart, 00168, Rome, Italy.
FAU - Mastrapasqua, Rodolfo F
AU  - Mastrapasqua RF
AD  - ENT Department, Rivoli Hospital, ASL TORINO 3, 10098, Turin, Italy.
FAU - Porru, Davide P
AU  - Porru DP
AD  - Department of Head-Neck and Sensory Organs, Catholic University of Sacred Heart, 
      00168, Rome, Italy.
FAU - D'Auria, Leandro M
AU  - D'Auria LM
AUID- ORCID: 0009-0007-7101-1080
AD  - Department of Head-Neck and Sensory Organs, Catholic University of Sacred Heart, 
      00168, Rome, Italy.
FAU - D'Agostino, Giuseppe
AU  - D'Agostino G
AUID- ORCID: 0000-0002-2518-3435
AD  - Department of Head-Neck and Sensory Organs, Catholic University of Sacred Heart, 
      00168, Rome, Italy.
FAU - Penazzi, Daniele
AU  - Penazzi D
AD  - Department of Head-Neck and Sensory Organs, Catholic University of Sacred Heart, 
      00168, Rome, Italy.
FAU - De Maio, Gabriele
AU  - De Maio G
AD  - Department of Head-Neck and Sensory Organs, Catholic University of Sacred Heart, 
      00168, Rome, Italy.
FAU - Onori, Maria E
AU  - Onori ME
AD  - Unit of Chemistry, Biochemistry and Molecular Biology, "A. Gemelli" Hospital 
      Foundation IRCCS, 00168, Rome, Italy.
FAU - Sarlo, Francesca
AU  - Sarlo F
AD  - Unit of Chemistry, Biochemistry and Molecular Biology, "A. Gemelli" Hospital 
      Foundation IRCCS, 00168, Rome, Italy.
FAU - Corbo', Marco
AU  - Corbo' M
AD  - Department of Head-Neck and Sensory Organs, Catholic University of Sacred Heart, 
      00168, Rome, Italy.
FAU - Galli, Jacopo
AU  - Galli J
AUID- ORCID: 0000-0003-1599-4573
AD  - Unit of Otorhinolaryngology and Head-Neck Surgery, "A. Gemelli" Hospital 
      Foundation IRCCS, 00168, Rome, Italy.
AD  - Department of Head-Neck and Sensory Organs, Catholic University of Sacred Heart, 
      00168, Rome, Italy.
LA  - eng
PT  - Journal Article
DEP - 20231229
PL  - Germany
TA  - Eur Arch Otorhinolaryngol
JT  - European archives of oto-rhino-laryngology : official journal of the European 
      Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the 
      German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
JID - 9002937
RN  - 420K487FSG (dupilumab)
RN  - 0 (Antibodies, Monoclonal, Humanized)
SB  - IM
MH  - Humans
MH  - *Nasal Polyps
MH  - *Sinusitis
MH  - *Rhinitis
MH  - Chronic Disease
MH  - *Eosinophilia/drug therapy
MH  - *Antibodies, Monoclonal, Humanized
OTO - NOTNLM
OT  - Biological therapy
OT  - Blood eosinophilia
OT  - Chronic rhinosinusitis with nasal polyps
OT  - Dupilumab
OT  - Hyper-eosinophilia
EDAT- 2024/01/02 11:45
MHDA- 2024/04/18 06:44
CRDT- 2023/12/29 11:06
PHST- 2023/11/15 00:00 [received]
PHST- 2023/12/11 00:00 [accepted]
PHST- 2024/04/18 06:44 [medline]
PHST- 2024/01/02 11:45 [pubmed]
PHST- 2023/12/29 11:06 [entrez]
AID - 10.1007/s00405-023-08417-8 [pii]
AID - 10.1007/s00405-023-08417-8 [doi]
PST - ppublish
SO  - Eur Arch Otorhinolaryngol. 2024 May;281(5):2429-2440. doi: 
      10.1007/s00405-023-08417-8. Epub 2023 Dec 29.